ɑO-Conotoxin GeXIVA isomers modulate N-type calcium (Ca
Analgesics, Non-Narcotic
/ chemistry
Animals
Calcium Channels, N-Type
/ drug effects
Conotoxins
/ chemistry
G Protein-Coupled Inwardly-Rectifying Potassium Channels
/ drug effects
Ganglia, Spinal
/ drug effects
HEK293 Cells
Humans
Male
Mice
Mice, Inbred C57BL
Neurons
/ drug effects
Protein Isoforms
Receptors, GABA-B
/ drug effects
G protein-coupled GABAB receptor
GIRK channel
calcium channel
conotoxin
dorsal root ganglion
neuroexcitability
patch clamp
Journal
Journal of neurochemistry
ISSN: 1471-4159
Titre abrégé: J Neurochem
Pays: England
ID NLM: 2985190R
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
revised:
28
10
2021
received:
23
07
2021
accepted:
28
10
2021
pubmed:
6
11
2021
medline:
12
2
2022
entrez:
5
11
2021
Statut:
ppublish
Résumé
αO-Conotoxin GeXIVA is a 28 amino acid peptide derived from the venom of the marine snail Conus generalis. The presence of four cysteine residues in the structure of GeXIVA allows it to have three different disulfide isomers, that is, the globular, ribbon or bead isomer. All three isomers are active at α9α10 nicotinic acetylcholine receptors, with the bead isomer, GeXIVA[1,2], being the most potent and exhibiting analgesic activity in animal models of neuropathic pain. The original report of GeXIVA activity failed to observe any effect of the isomers on high voltage-activated (HVA) calcium channel currents in rat dorsal root ganglion (DRG) neurons. In this study, we report, for the first time, the activity of globular GeXIVA[1,3] at G protein-coupled GABA
Substances chimiques
Analgesics, Non-Narcotic
0
Calcium Channels, N-Type
0
Conotoxins
0
G Protein-Coupled Inwardly-Rectifying Potassium Channels
0
Protein Isoforms
0
Receptors, GABA-B
0
alpha-conotoxin, Conus generalis
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
154-171Informations de copyright
© 2021 International Society for Neurochemistry.
Références
Adams, D. J., & Berecki, G. (2013). Mechanisms of conotoxin inhibition of N-type (Cav2.2) calcium channels. Biochimica Et Biophysica Acta (BBA) - Biomembranes, 1828(7), 1619-1628. https://doi.org/10.1016/j.bbamem.2013.01.019
Adams, D. J., Callaghan, B., & Berecki, G. (2012). Analgesic conotoxins: block and G protein-coupled receptor modulation of N-type (CaV2.2) calcium channels. British Journal of Pharmacology, 166, 486-500. https://doi.org/10.1111/j.1476-5381.2011.01781.x
Benke, D. (2020). GABAB receptors and pain. In S. Vlachou & K. Wickman (Eds.), Behavioral neurobiology of GABAB receptor function. Current Topics in Behavioral Neurosciences (1st ed., 28pp.). Springer International Publishing. https://doi.org/10.1007/7854_2020_130
Berecki, G., McArthur, J. R., Cuny, H., Clark, R. J., & Adams, D. J. (2014). Differential Cav2.1 and Cav2.3 channel inhibition by baclofen and α-conotoxin Vc1.1 via GABAB receptor activation. Journal of General Physiology, 143(4), 465-479. https://doi.org/10.1085/jgp.201311104
Blednov, Y. A., Stoffel, M., Alva, H., & Harris, R. A. (2003). A pervasive mechanism for analgesia: Activation of GIRK2 channels. Proceedings of the National Academy of Sciences of the United States of America, 100, 277-282. https://doi.org/10.1073/pnas.012682399
Bony, A. R., McArthur, J. R., Finol-Urdaneta, R. K., & Adams, D. J. (2021). Analgesic α-conotoxins modulate GIRK1/2 channels via GABAB receptor activation and reduce neuroexcitability. British Journal of Pharmacology, https://doi.org/10.1111/bph.15690
Callaghan, B., Haythornthwaite, A., Berecki, G., Clark, R. J., Craik, D. J., & Adams, D. J. (2008). Analgesic α-conotoxins Vc1.1 and RgIA inhibit N-type calcium channels in rat sensory neurons via GABAB receptor activation. Journal of Neuroscience, 28, 10943-10951. https://doi.org/10.1523/JNEUROSCI.3594-08.2008
Campbell, V., Berrow, N., & Dolphin, A. C. (1993). GABAB receptor modulation of Ca2+ currents in rat sensory neurons by the G-protein Go: Antisense oligonucleotide studies. Journal of Physiology, 470, 1-11. https://doi.org/10.1113/jphysiol.1993.sp019842
Carstens, B. B., Swedberg, J., Berecki, G., Adams, D. J., Craik, D. J., & Clark, R. J. (2016). Effects of linker sequence modifications on the structure, stability and biological activity of a cyclic α-conotoxin. Biopolymers, 106(6), 864-875. https://doi.org/10.1002/bip.22848
Clark, R. J., Jensen, J., Nevin, S. T., Callaghan, B. P., Adams, D. J., & Craik, D. J. (2010). The engineering of an orally active conotoxin for the treatment of neuropathic pain. Angewandte Chemie International Edition, 49(37), 6545-6548. https://doi.org/10.1002/anie.201000620
Costigan, M., Scholz, J., & Woolf, C. J. (2009). Neuropathic pain: A maladaptive response of the nervous system to damage. Annual Review of Neuroscience, 32, 1-32. https://doi.org/10.1146/annurev.neuro.051508.135531
Cuny, H., de Faoite, A., Huynh, T. G., Yasuda, T., Berecki, G., & Adams, D. J. (2012). γ-Aminobutyric acid type B (GABAB) receptor expression is needed for inhibition of N-type (Cav2.2) calcium channels by analgesic α-conotoxins. Journal of Biological Chemistry, 287(28), 23948-23957. https://doi.org/10.1074/jbc.M112.342998
Daly, N. L., Callaghan, B., Clark, R. J., Nevin, S. T., Adams, D. J., & Craik, D. J. (2011). Structure and activity of α-conotoxin PeIA at nicotinic acetylcholine receptor subtypes and GABAB receptor-coupled N-type calcium channels. Journal of Biological Chemistry, 286(12), 10233-10237. https://doi.org/10.1074/jbc.M110.196170
Finnerup, N. B., Kuner, R., & Jensen, T. S. (2021). Neuropathic pain: From mechanisms to treatment. Physiological Reviews, 101, 259-301. https://doi.org/10.1152/physrev.00045.2019
Furukawa, T., Nukada, T., Mori, Y., Wakamori, M., Fujita, Y., Ishida, H., Fukuda, K., Kato, S., & Yoshii, M. (1998). Differential interactions of the C terminus and the cytoplasmic I-II loop of neuronal Ca2+ channels with G-protein ɑ and βγ subunits. I. Molecular determination. Journal of Biological Chemistry, 273, 17585-17594. https://doi.org/10.1074/jbc.273.28.17585
Gallo, C., Abram, K., Hannah, N., Caton, L., Cimaglio, B., McGovern, M., & Brown, C. H. (2021). Sustainability planning in the US response to the opioid crisis: An examination using expert and text mining approaches. PLoS One, 16(1), e0245920. https://doi.org/10.1371/journal.pone.0245920
Gao, X. F., Zhang, H. L., You, Z. D., Lu, C. L., & He, C. (2007). G protein-coupled inwardly rectifying potassium channels in dorsal root ganglion neurons. Acta Pharmacologica Sinica, 28, 185-190. https://doi.org/10.1111/j.1745-7254.2007.00478.x
Halai, R., Callaghan, B., Daly, N. L., Clark, R. J., Adams, D. J., & Craik, D. J. (2011). Effects of cyclization on stability, structure and activity of α-conotoxin RgIA at the α9α10 nicotinic acetylcholine receptor and GABAB receptor. Journal of Medicinal Chemistry, 54, 6984-6992. https://doi.org/10.1021/jm201060r
Halai, R., Clark, R. J., Nevin, S. T., Jensen, J. E., Adams, D. J., & Craik, D. J. (2009). Scanning mutagenesis of α-conotoxin Vc1.1 reveals residues crucial for activity at the α9α10 nicotinic acetylcholine receptor. Journal of Biological Chemistry, 284(30), 20275-20284. https://doi.org/10.1074/jbc.M109.015339
Huynh, T. G., Cuny, H., Slesinger, P. A., & Adams, D. J. (2015). Novel mechanism of voltage-gated N-type (Cav2.2) calcium channel inhibition revealed through α-conotoxin Vc1.1 activation of the GABAB receptor. Molecular Pharmacology, 87, 240-250. https://doi.org/10.1124/mol.114.096156
Jeremic, D., Sanchez-Rodriguez, I., Jimenez-Diaz, L., & Navarro-Lopez, J. D. (2021). Therapeutic potential of targeting G protein-gated inwardly rectifying potassium (GIRK) channels in the central nervous system. Pharmacology and Therapeutics, 223, 107808. https://doi.org/10.1016/j.pharmthera.2021.107808
Jin, A. H., Muttenthaler, M., Dutertre, S., Himaya, S. W. A., Kaas, Q., Craik, D. J., Lewis, R. J., & Alewood, P. F. (2019). Conotoxins: Chemistry and biology. Chemical Reviews, 119(21), 11510-11549. https://doi.org/10.1021/acs.chemrev.9b00207
Lewis, R. J., Dutertre, S., Vetter, I., & Christie, M. J. (2012). Conus venom peptide pharmacology. Pharmacological Reviews, 64, 259-298. https://doi.org/10.1124/pr.111.005322
Li, X., Hu, Y., Wu, Y., Huang, Y., Yu, S., Ding, Q., Zhangsun, D., & Luo, S. (2016). Anti-hypersensitive effect of intramuscular administration of αO-conotoxin GeXIVA[1,2] and GeXIVA[1,4] in rats of neuropathic pain. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 66, 112-119. https://doi.org/10.1016/j.pnpbp.2015.12.005
Luo, S., Zhangsun, D., Harvey, P. J., Kaas, Q., Wu, Y., Zhu, X., Hu, Y., Li, X., Tsetlin, V. I., Christensen, S., Romero, H. K., McIntyre, M., Dowell, C., Baxter, J. C., Elmslie, K. S., Craik, D. J., & McIntosh, J. M. (2015). Cloning, synthesis, and characterization of αO-conotoxin GeXIVA, a potent α9α10 nicotinic acetylcholine receptor antagonist. Proceedings of the National Academy of Sciences of the United States of America, 112, E4026-4035. https://doi.org/10.1073/pnas.1503617112
Luscher, C., & Slesinger, P. A. (2010). Emerging roles for G protein-gated inwardly rectifying potassium (GIRK) channels in health and disease. Nature Reviews Neuroscience, 11(5), 301-315. https://doi.org/10.1038/nrn2834
Malcangio, M. (2018). GABAB receptors and pain. Neuropharmacology, 136, 102-105. https://doi.org/10.1016/j.neuropharm.2017.05.012
McGivern, J. G. (2007). Ziconotide: a review of its pharmacology and use in the treatment of pain. Neuropsychiatric Disease and Treatment, 3(1), 69-85. https://doi.org/10.2147/nedt.2007.3.1.69
Prashanth, J. R., Brust, A., Jin, A.-H., Alewood, P. F., Dutertre, S., & Lewis, R. J. (2014). Cone snail venomics: from novel biology to novel therapeutics. Future Medicinal Chemistry, 6(15), 1659-1675. https://doi.org/10.4155/fmc.14.99
Sadeghi, M., Carstens, B. B., Callaghan, B. P., Daniel, J. T., Tae, H.-S., O'Donnell, T., Castro, J., Brierley, S. M., Adams, D. J., Craik, D. J., & Clark, R. J. (2018). Structure-activity studies reveal the molecular basis for GABAB-receptor mediated inhibition of high voltage-activated calcium channels by α-conotoxin Vc1.1. ACS Chemical Biology, 13(6), 1577-1587. https://doi.org/10.1021/acschembio.8b00190
Sadeghi, M., McArthur, J. R., Finol-Urdaneta, R. K., & Adams, D. J. (2017). Analgesic conopeptides targeting G protein-coupled receptors reduce excitability of sensory neurons. Neuropharmacology, 127, 116-123. https://doi.org/10.1016/j.neuropharm.2017.05.020
Safavi-Hemami, H., Brogan, S. E., & Olivera, B. M. (2019). Pain therapeutics from cone snail venoms: From Ziconotide to novel non-opioid pathways. Journal of Proteomics, 190, 12-20. https://doi.org/10.1016/j.jprot.2018.05.009
Sun, Z., Bao, J., Zhangsun, M., Dong, S., Zhangsun, D., & Luo, S. (2020). αO-Conotoxin GeXIVA inhibits the growth of breast cancer cells via interaction with α9 nicotine acetylcholine receptors. Marine Drugs, 18(4), 195. https://doi.org/10.3390/md18040195
Sun, Z., Zhangsun, M., Dong, S., Liu, Y., Qian, J., Zhangsun, D., & Luo, S. (2020). Differential expression of nicotine acetylcholine receptors associates with human breast cancer and mediates antitumor activity of αO-conotoxin GeXIVA. Marine Drugs, 18(1), 61. https://doi.org/10.3390/md18010061
Terlau, H., & Olivera, B. M. (2004). Conus venoms: a rich source of novel ion channel-targeted peptides. Physiological Reviews, 84(1), 41-68. https://doi.org/10.1152/physrev.00020.2003
Wang, H., Li, X., Zhangsun, D., Yu, G., Su, R., & Luo, S. (2019). The α9α10 nicotinic acetylcholine receptor antagonist αO-conotoxin GeXIVA[1,2] alleviates and reverses chemotherapy-induced neuropathic pain. Marine Drugs, 17(5), 265. https://doi.org/10.3390/md17050265
Waxman, S. G., & Zamponi, G. W. (2014). Regulating excitability of peripheral afferents: emerging ion channel targets. Nature Neuroscience, 17(2), 153-163. https://doi.org/10.1038/nn.3602
Wu, X., Huang, Y. H., Kaas, Q., Harvey, P. J., Wang, C. K., Tae, H.-S., Adams, D. J., & Craik, D. J. (2017). Backbone cyclization of analgesic conotoxin GeXIVA facilitates direct folding of the ribbon isomer. Journal of Biological Chemistry, 292(41), 17101-17112. https://doi.org/10.1074/jbc.M117.808386
Xu, P., Kaas, Q., Wu, Y., Zhu, X., Li, X., Harvey, P. J., Zhangsun, D., Craik, D. J., & Luo, S. (2020). Structure and activity studies of disulfide-deficient analogues of αO-conotoxin GeXIVA. Journal of Medicinal Chemistry, 63(4), 1564-1575.
Zamponi, G. W., & Currie, K. P. (2013). Regulation of CaV2 calcium channels by G protein coupled receptors. Biochimica et Biophysica Acta (BBA) - Biomembranes, 1828(7), 1629-1643. https://doi.org/10.1016/j.bbamem.2012.10.004
Zhangsun, D., Zhu, X., Kaas, Q., Wu, Y., Craik, D. J., McIntosh, J. M., & Luo, S. (2017). αO-Conotoxin GeXIVA disulfide bond isomers exhibit differential sensitivity for various nicotinic acetylcholine receptors but retain potency and selectivity for the human α9α10 subtype. Neuropharmacology, 127, 243-252. https://doi.org/10.1016/j.neuropharm.2017.04.015